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Cetuximab (CTX) is a potent chimeric mouse/human monoclonal antibody (mAb) approved worldwide
for treatment of metastatic colorectal cancer. Among the various biological and physical analyses per-
formed for full study on this biopharmaceutic, the determination of the concentration preparations
throughout manufacturing and subsequent handling in hospital is particularly relevant. In the present
work, the study and validation of a method for quantifying intact CTX by reverse-phase high-perfor-
mance liquid chromatography with diode array detection ((RP)HPLC/DAD) is presented. With that end,
we checked the performance of a chromatographic method for quantifying CTX and conducted a study to
validate the method as stability-indicating in accordance with the International Conference on Harmo-
nization guidelines (ICH) for biotechnological drugs; therefore, we evaluated linearity, accuracy, preci-
sion, detection and quantiﬁcation limits, robustness and system suitability. The speciﬁcity of the method
and the robustness of the mAb formulation against external stress factors were estimated by compre-
hensive chromatographic analysis by subjecting CTX to several informative stress conditions. As de-
monstrated, the method is rapid, accurate, and reproducible for CTX quantiﬁcation. It was also suc-
cessfully used to quantify CTX in a long-term stability study performed under hospital conditions.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cetuximab (CTX) is a potent chimeric mouse/human mono-
clonal antibody (mAb) approved worldwide for the treatment of
colon and head and neck cancers. It is directed against the human
epidermal growth factor receptor (EGFR) [1]. Of the ﬁve classes of
antibodies in humans, CTX is an immunoglobulin G (IgG) from
Subclass 1 (IgG1), the most commonly used subclass for pharma-
ceutical and biomedical purposes [2] (Fig. 1). Due to the increasing
importance of this class of biopharmaceuticals, a dynamic ﬁeld of
research has arisen around the development of analytical methods
for their detailed characterization.
MAbs including IgG1 are large glycoproteins (E150 kDa),on and hosting by Elsevier B.V. Th
University.composed of four peptide chains, two identical heavy chains
(E50 kDa) and two identical light chains (E25 kDa), which are
connected by disulﬁde bonds (Fig. 1) at their hinge region [3], giving
them a speciﬁc Y shape. From the structural point of view, mass
spectrometry (MS) is the most versatile technology for the in-depth
structural analysis of mAbs [4,5]. MS can be used for the char-
acterization of both small and large chemical changes in the mAbs,
i.e., primary amino acid elucidation, glycosylation proﬁles and post-
translational modiﬁcation such as deamidation and oxidation. In
recent research, several structural approaches based on MS tech-
niques were used to assess the primary amino acid sequence, the
glyco-proﬁle of CTX, and the mAb studied here [6]. Nevertheless,
problems arise when intact mAbs analysis has to be performed
coupled to a liquid chromatographic (LC) system. In this case, when
performing liquid chromatography–electrospray ionization–mass
spectrometry (LC–ESI–MS) analysis, the uncommon solvent systems
used for the elution of the mAbs from the latest generation of
chromatographic columns complicate the ionization process in theis is an open access article under the CC BY-NC-ND license
Fig. 1. General structure of IgG1.
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used for quantifying intact mAbs by LC–MS [7], and none of them has
been validated following the International Conference for Harmoni-
zation (ICH) guidelines. The quantiﬁcation of therapeutic mAbs was
carried out by enzyme-linked immuno sorbent assay (ELISA) [8,9].
However, the lower precision (about 10% of relative standard devia-
tion in repeatability) and robustness of the immunoassays compared
with physicochemical-based techniques led ICH to recommend the
latter for quantiﬁcation purposes (Q6B) [10].
Among the different modes of LC, reverse-phase (RP)–LC ap-
pears to be one of the most promising analytical techniques for the
study of peptides and intact protein, including mAbs [11–13]. RP–
LC is generally more efﬁcient than ion-exchange (IXC) and size-
exclusion chromatography (SEC) [14], making it the best technique
for quantiﬁcation purposes [15]. Furthermore, RP–LC has a quicker
separation time than IXC. However, taking into account that
several methods are required to perform a rigorous study of a
biopharmaceutical, IXC is the most suitable method for tracking
charge proﬁle [16] and SEC for detecting mAb aggregates [17].
The use of stationary phases with wider pores (300 Å) and long
alkyl chains (C8 and C18) together with a high column tempera-
ture (60–75 °C) and a combination of non-traditional solvent
systems with ion pairing agents [18,19] is gradually being con-
solidated as the established procedure for RP chromatographic
analysis of intact mAbs. However, the small chemical differences
produced by deamidation, cysteine oxidation or the heterogeneity
in the glycans proﬁle of the mAbs generate such small changes in
the polarity of the molecules that LC columns currently available
cannot separate them chromatographically [20]. Chromatographic
separation of marketed mAbs is not successful for the same reason,
i.e., the chemical differences between them are insufﬁcient to
bring about signiﬁcant changes in the polarity that enable them to
be separated chromatographically [15].
From the point of view of the analytical validation of bio-
pharmaceuticals, the ICH Q6B guidelines [10] indicate that the
validation of analytical procedures used in the characterization of
biotechnological products (such as therapeutic mAbs) should be
performed in compliance with the ICH Q2(R1) guidelines relating
to the validation of analytical procedures [21]. Despite the fact that
ICH Q2(R1) was originally developed for low-molecular-weight
drugs, it can also be adapted for use with biotechnology-based
pharmaceuticals. In a recently published work [15], we proposed
that the quantiﬁcation of intact rituximab (RTX), another mar-
keted mAb IgG1, could be achieved using a reverse-phase high-
performance liquid chromatography with diode array detection((RP)HPLC/DAD) method validated according to the ICH Q2(R1)
guidelines. We proposed that the method was validated as stabi-
lity-indicating for quantiﬁcation since it was qualiﬁed for detecting
modiﬁcation/degradation by means of the peak purity analysis
proposed, even though total chromatographic separation was not
achieved in the stress study we performed. In the present study,
we analyzed the performance of (RP)HPLC/DAD and discussed the
validation of the method for the quantiﬁcation of the intact CTX.2. Materials and methods
2.1. Chemicals and reagents
Erbitux
s
(Merck KGaA, Darmstad, Germany) was used as a re-
presentative CTX reference material. The daily surplus was kindly
supplied for this study by the Pharmacy Unit of the University
Hospital “San Cecilio” (Granada, Spain). All of the standard solu-
tions of CTX were prepared from this medicine. The speciﬁcations
for the medicine indicated that there were 100 mg/20 mL of CTX in
each single-use vial along with sodium citrate, polysorbate 80,
sodium chloride, glycine, citric monohydrate acid, sodium hydro-
xide and water for injections, giving a ﬁnal concentration of
5 mg/mL of CTX [2]. The working standard solutions of CTX were
prepared daily from marketed CTX (immediately after opening it)
by appropriate dilution with 0.9% NaCl aqueous solution. Different
batches were used randomly throughout the study.
All reagents were of analytical reagent grade unless otherwise
stated. Reverse-osmosis-quality water puriﬁed (Z18 MΩ/cm) with
a Milli-RO plus Milli-Q station from Millipore Corp. (Madrid, Spain)
was used throughout the study. Methanol of HPLC grade, hydro-
chloric acid, sodium chloride and sodium hydroxide (pure for ana-
lysis) and propan-2-ol (Z98.0%) were supplied by Panreac (Barce-
lona, Spain). Hydrogen peroxide (30%) was supplied by Technical
(Fontenay-sous-Bois, France). Triﬂuoroacetic acid (Z98.0%) (TFA)
was from Merck KGaA (Darmstadt, Germany) and HPLC grade
acetonitrile was from Poch S.A. (Gliwice, Poland). An isotonic solu-
tion of 0.9% NaCl was supplied by B. Braun Medical (Madrid, Spain).
2.2. CTX standard sample solutions
All of the standard solutions of CTX were prepared from the
medicine Erbitux
s
. The working standard solutions of CTX were
prepared daily from marketed CTX (immediately after opening it)
by appropriate dilution with 0.9% NaCl aqueous solution. We in-
tended to avoid any kind of change or degradation in the mAb due
to its complex protein nature. Also, different batches were used
randomly throughout the study.
2.3. Chromatographic system and software
All chromatographic analyses were performed using an Agilent
110 HPLC system equipped with a quaternary pump, a degasser, an
autosampler, a column oven and a photodiode array detector
(Agilent Technologies, Madrid, Spain). The instrument was con-
nected to a personal computer ﬁtted with an HPLC ChemStation
workstation for LC 3D systems (rev. A.0903) (Agilent Technolo-
gies). Chromatographic conditions are summarized in Table 1.
The Statgraphics Plus 6.0 (Statistical Graphics System, 1992,
Warrenton, VA, USA) statistical software package was used to deal
with the chromatographic data.
2.4. Analytical method validation
2.4.1. Linearity, LOD, and LOQ
Linearity was evaluated up to 5.0 mg/mL. To this end, appropriate
Table 1
Chromatographic conditions.
Column Zorbax 300 SB-C8 (150 mm2.1 mm, 5 μm, Agilent
Technologies)
Eluent A: Milli-Q water and 0.1% TFA
B: iPrOH, ACN, Milli-Q water and TFA (70:20:9.9:0.1, v/v/
v/v)
Elution Gradient program (time, % B): 0–1 min, 10% B;
1–1.05 min, 20% B; 1.05–4 min, 20% B; 4–4.05 min,
30% B; 4.05–10 min, 60% B, 10–10.05 min, 80% B;
10.05–12 min, 80% B; post-time: 3 min
Flow rate 1 mL/min
Injection volume 1 μL
Column
temperature
70 °C
Autosampler
temperature
25 °C
Injection washing
solution
Milli-Q water
Detection 214 nm
280 nm (reference)
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prepared in quadruplicate and injected into the chromatographic
system. A linear calibration function was ﬁtted by least-squares re-
gression, and linearity was accepted, if the statistical probability level
in the corresponding lack-of-ﬁt test (the PLOF-value) was greater than
5% according to the Analytical Methods Committee [22].
The limit of detection (LOD) and the limit of quantiﬁcation
(LOQ) were estimated from the standard deviation (SD) of the
lowest concentration tested. LOD and LOQ were calculated as
3 SD and 10 SD, respectively.
2.4.2. Precision
The precision of the method was tested by estimating the intra-
day precision (repeatability) and the intermediate precision (5
days, reproducibility), given as relative standard deviations (RSDs).
The former was estimated from the results of the analysis of CTX
standard solutions prepared at the same concentration on the
same day. Thirty samples with high-concentration levels (10
samples of 5.0 mg/mL), medium-concentration levels (10 samples
of 2.0 mg/mL), and low-concentration levels (10 samples of
0.5 mg/mL) were used for this purpose. The intermediate precision
was estimated from the analysis of standard solutions at three
concentration levels (0.5, 2.0 and 5.0 mg/mL) over ﬁve consecutive
days. Two samples of each concentration were prepared and
analyzed daily (ten samples of each concentration tested).
Because ICH Q2(R1) [21] does not establish any precision cri-
teria for acceptance of the method, the US Food and Drug Ad-
ministration (USFDA) criteria for HPLC methods for pharmaceu-
tical analysis were followed [23,24], i.e., an intra-day precision
ofr2%.
2.4.3. Accuracy
The accuracy of the method was assessed from the average
recovery value calculated by analyzing ten standard solution re-
plicates at three concentration levels representing the highest
value (5.0 mg/mL), the middle value (2.0 mg/mL), and the lowest
value (0.5 mg/mL) of the calibration scale, in order to cover the
stated linear range. Once again, ICH Q2(R1) [21] does not indicate
criteria for acceptance of the accuracy of the method. We, there-
fore, decided to follow the USFDA accuracy criteria for HPLC
methods for pharmaceutical analysis [23,24], i.e., an average re-
covery of (10070.1)%.
2.4.4. Speciﬁcity
Forced degradation studies were performed using dilutedErbitux
s
sample solutions of 2.0 mg/mL of CTX in 0.9% NaCl. ICH
Q5C [25] recommends that stability testing should be carried out
at representative concentrations of the ﬁnal product, which, in the
case of typical hospital conditions for CTX, would be in the range
of 2.0–5.0 mg/mL for injected solutions for perfusion [1]. The
lowest concentration was used for the stress study. The stress
conditions studied were high temperature, high ionic strength,
light exposure, addition of an acid and a base, and addition of an
oxidant. The chromatograms for the stressed samples were com-
pared with those for a freshly prepared CTX standard solution that
had not undergone degradation treatment. All samples were
analyzed in triplicate.
Two levels of stress conditions were tested when the CTX sample
was put under stress using acid (1 M HCl), alkaline (0.1 M NaOH),
ionic (1.5 M NaCl) and oxidative media (1 M H2O2). For the lower
level stress condition, the concentration of the stressed agent was
3.3% (v/v) (50 mL of the stressed agent was added to 1.5 mL of mAb
standard solution), while for the higher level stress condition, the
stressed agent concentration was 25% (v/v) (500 mL of the stressed
agent was added to 1.5 mL of mAb standard solution). The samples
were analyzed 24 h after preparation. The effect of high temperature
was evaluated by placing aliquots of the CTX standard solution in an
oven (Heraeus S.A., Madrid, Spain) at the temperature of 50 °C for
24 h, which is considered the maximum temperature to which
samples could be accidentally exposed in hospital. After the speciﬁed
time had elapsed, the solutions were analyzed. The effect of light was
investigated by placing aliquots of the CTX standard solution samples
in an accelerated stress test chamber to simulate sun light (Solarbox
3000e RH, Cofomegra, Milan, Italy). The samples were light irradiated
with a xenon lamp using a UV ﬁlter S208/S408 soda lime glass ﬁlter
to simulate indoor exposure conditions with infrared rejection
coating to reduce samples temperature. The temperature was con-
trolled and maintained at 24 °C (considered as room temperature).
Irradiance was set up at 250W/m2 between 300 and 800 nm.
Spectral peak purity was checked using the corresponding
ChemStation software [26,27]. In brief, this assessment was based
on a comparison of all the spectra recorded during the elution of
the peak, one every 0.2 min, and on the calculation of a similarity
function based on the regression coefﬁcient (R2). All of the spectra
in the chromatographic peak were averaged to obtain a pooled
spectrum which was compared with all the spectra in the peak to
obtain the similarity function. The similarity factor was set to a
value of Z99.0% for acceptance of the spectral peak purity.
2.4.5. System suitability
For system suitability testing, we used standard samples of
2.0 mg/mL prepared in 0.9% NaCl. ICH Q2(R1) [21] does not indicate
criteria for the acceptance of system suitability either. We, therefore,
decided to follow the USFDA criteria for HPLC methods of phar-
maceutical analysis [23,24], although we used the symmetry factor
instead of the asymmetry ratio of a peak. The selected system
suitability parameters were N (acceptance criterion N42000), k′
(acceptance criterion k ′42.0), S (acceptance criterion Sr2), and
injection repeatability (acceptance criterion RSDr1%).
2.4.6. Robustness
Robustness was evaluated by making small changes in the
mobile phase composition (B75%), the mobile phase ﬂow rate
(70.1 mL) and the temperature (tested from 60 to 70 °C), and
these parameters mostly affect the chromatographic process. Ali-
quots of the CTX standard solution of 2.0 mg/mL were analyzed at
each modiﬁed condition to assess the impact of the condition on
the assay results. The robustness of the method was then esti-
mated in terms of the retention time, the symmetry factor (S), the
capacity factor (k′), and the number of theoretical plates (N).
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conditions)
A diluted CTX sample of 2.0 mg/mL in 0.9% NaCl was prepared
from the medicine Erbitux
s
as indicated in the scientiﬁc technical
report for CTX [1]. This CTX sample was divided into 1 mL of ali-
quots and placed in amber glass vials (protected from daylight).
One aliquot was stored refrigerated at 4 °C, and several aliquots
were stored frozen at 20 °C. In the long-term study, the con-
centration of CTX was expressed as the percentage of the initial
mAb concentration remaining at each checked time, where the
initial concentration was that on the day when the samples were
prepared (Day 0). In all cases, the reported concentration is the
average of three replicates. The refrigerated sample was analyzed
1, 3, 7, 14 and 31 days after preparation. The frozen samples were
analyzed after a month.3. Results and discussion
3.1. Method development
The (RP)HPLC/DAD method previously developed for the ana-
lysis of intact RTX [15] was here checked for the analysis of CTX. In
brief, we used a Zorbax 300 SB C8 analytical column because of its
reported excellent temperature stability at low pH [28]; the mobile
phase was a combination of isopropanol (i-PrOH), acetonitrile
(ACN), water and triﬂuoroacetic acid (TFA), a strong eleutropic
solvent system required for the analysis of antibodies in order to
reduce column interactions due to their high hydrophobicity [19].
The conditions used in the gradient allowed the elution of the
intact CTX at a retention time between 7 and 8 min. This enables
both a rapid result, which is important for routine analysis, and
separation of CTX from degradation products, as occurs for
example when subjected to oxidative stress conditions (discussed
below). As in the previous work [15], two equilibration steps of the
column were necessary to elute the mAb at the selected retention
time (between 7 and 8 min), and without these steps, a small
chromatographic peak from the system solvent overlapped with
the chromatographic peak of the mAb (see Fig. 2, chromatographic
peak at approximately 7 min). The peaks at 4 and 7 min were from
the solvent system because they were detected when we injected
water into samples (blank samples) (Fig. 2d). Despite using a post-
time of 3 min with 10% phase B (the initial gradient conditions) to
equilibrate the column, an extra minute was necessary underFig. 2. Standard solutions of 5000 mg/L (a), 2500 mg/L (b), and 1000 mg/L (c) of
CTX standard samples analyzed by (RP)HPLC/DAD. UV absorption spectra recorded
at the chromatographic peak and the graphic results for the spectral peak purity
analysis using 99.3% as similarity factor. Chromatogram of a blank sample (d). UV
absorption spectra recorded at the peak (e). Results from peak purity analysis (f).these analytical conditions to avoid changes in the retention time
of the chromatographic peak of the mAb. As described in the lit-
erature and later conﬁrmed in a robustness study, slight changes
in the mobile phase composition are critical in the elution of mAbs
[18,19]. We also corroborated that column temperature was a
critical chromatographic parameter. CTX was not eluted at tem-
peratures below 50 °C; with the increase of the temperature, CTX
was eluted with a narrower and well deﬁned chromatographic
peak. Then, we selected 70 °C, the maximum value speciﬁed for
this column. The chromatograms were recorded at different wa-
velengths (λ¼214 nm, 220 nm, 254 nm, and 280 nm), using λ¼
(360720) nm as the reference wavelength in all cases. The ana-
lytical parameters of the method were calculated using λ¼214 nm,
because it was the maximum absorption and the signal was less
affected by the inherent heterogeneity of CTX.
In this way, we conﬁrmed that the conditions selected for
quantifying intact RTX are also suitable for the quantiﬁcation of
CTX. No appreciable differences were detected either in the
chromatographic behavior or in the UV spectra of the two mAbs.
Fig. 2 shows the chromatograms for CTX standard solutions
under the chromatographic conditions. The UV absorption spectra
recorded at the peak are also displayed (Fig. 2e), together with the
results from the peak purity analysis (Fig. 2f), both of which are
discussed in the next section.
3.2. Analytical method validation
The medicine Erbitux was used throughout the study as re-
ference standard material for CTX. It is the marketed form of CTX
and none of the ingredients interfere with the chromatographic
analysis. In addition, in order to avoid any kind of change or de-
gradation in CTX, the working standard solutions were prepared
daily from the medicine (immediately after opening it) by appro-
priate dilution with 0.9% NaCl aqueous solution.
3.2.1. Linearity, LOD, and LOQ
The linearity of the method was corroborated up to 5.0 mg/mL,
considering 2.0 mg/mL as the CTX target concentration. These
concentrations were high, so the volume injected was as small as
possible, i.e., 1 μL. This was to avoid further dilution of the CTX
samples when prepared at hospital conditions of use, i.e., between
2.0 and 5.0 mg/mL, so that they could be injected into the chro-
matographic system without the need for any previous manip-
ulation that could bring about slight changes in the mAb. Higher
CTX concentrations gave wider chromatographic peaks. Table 2
shows the results of the calibration function. The intercept (a) wasTable 2
Performance of the analytical methods.
Figure of merit Value
Intercept (a) 9.84
Slope (b) 1.050
s (a)a 20.6
P-value (%)b 0.64
s (b)c 0.007
R2 d 0.999
P-value (%)e 0.194
Practical linear range (mg/mL) 0.5–5.00
Limit of quantiﬁcation (LOQ)f ( mg/mL) 0.21
Limit of detection (LOD)f (mg/mL) 0.06
a Standard deviation of the intercept.
b Probability of intercept signiﬁcant.
c Standard deviation of the slope.
d Determination coefﬁcient.
e Probability of lack-of-ﬁt test.
f Estimated from the SD of the intercept (a).
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5% whereas the slope (b) was signiﬁcant with a P-value close to 0.
The coefﬁcient of determination (R2), and the probability of a lack-
of-ﬁt (PLOF-value, %) indicated a high degree of ﬁt for the experi-
mental data to the linear model proposed. All criteria were ful-
ﬁlled, indicating that the linearity of the response of the detector
under the conditions selected for determining CTX was success-
fully demonstrated.
The LOD and LOQ were estimated as indicated in the Experi-
mental section. The working range was then established between
0.21 and 5.0 mg/mL, with the LOQ being the lowest concentration
in this range.
A proper quantiﬁcation strategy in routine analysis could be
implemented with this method since the null intercept and the
linearity of the calibration curve have been corroborated. Under
these conditions, the response factor (RF), deﬁned as the ratio
between the measured absorbance of a CTX-based medicine
sample and its CTX concentration, can be considered to remain
constant throughout the working range. To this end, one re-
presentative CTX standard can be analyzed with each analytical
batch, and quantiﬁcation was carried out by applying the esti-
mated RF value of the standard [29].
We also estimated the retention time of CTX. For this purpose,
we used 40 chromatograms of CTX standard samples obtained at
different concentrations and on different days, in order to gather
all possible sources of variation in the measurement of the re-
tention time. The average retention time calculated was 7.86 min
with SD of 0.06 min, which means that, for a conﬁdence level of
99.5% (t¼2.704, n¼40), the retention time interval of CTX was
estimated as 7.8670.06 min. This retention time overlapped with
the retention time of RTX (7.670.2 min) [15].
3.2.2. Accuracy
The accuracy (trueness and precision) of the analytical method
for quantifying intact CTX was veriﬁed across the linear range as
stated in the ICH Q2(R1) guidelines [21]. As shown in Table 3,
satisfactory results were obtained for the trueness and for both the
intra-day and inter-day precisions of the method, expressed as
recovery and relative standard deviation (RSD) values, respec-
tively. The intra-day and inter-day RSDs werer2% for all con-
centrations tested. The recovery values in all cases were close to
100% of the concentration checked, and the trueness fulﬁlled the
acceptance criterion by falling within the range 100%70.1%.
3.2.3. Speciﬁcity
Forced degradation studies were performed (according to the
ICH Q2(R1) guidelines [21]) on Erbitux
s
sample solutions to
evaluate the speciﬁcity of the proposed method. This stress study
was also carried out to gather information about the degradation
of the mAb under hospital conditions, as a means of evaluating the
robustness of this CTX formulation against external factors. The
stress factors we studied were those that could potentially affectTable 3
Precision and accuracy of the method.
Concentration tested (mg/mL) Recoverya (%) Precision (RSD, %)b
Intra-day Inter-day (5 days)
0.5 100 0.7 0.6
2.0 100.1 1.8 2.0
5.0 99.9 1.7 1.6
a Recovery value obtained from ten samples prepared from the standard.
b Relative standard deviation from ten standard samples.stability. Furthermore, whereas stability testing requirements
were deﬁned in regulatory guidelines, the particular procedures
for forced degradation studies of therapeutic proteins have not yet
been standardized [30]. We, therefore, carried out the forced de-
gradation studies described in the Experimental section.
Chromatographic separation of the modiﬁed/degraded CTX
was not always achieved. New chromatographic peaks that were
clearly separated from the CTX peak were only observed in the
ionic and oxidative stressed samples (Fig. 3). For these reasons,
we proposed three different aspects to test CTX degradation/
modiﬁcation. Firstly, we looked for new chromatographic peaks;
secondly, we evaluated CTX chromatographic peak deformation;
and thirdly, we carried out the peak purity analysis referred to
above [15]. Modiﬁcation/degradation of CTX could be detected by
gathering the information about these three aspects. The method
is, therefore, qualiﬁed to detect degradation/modiﬁcation,
although it can only be used to quantify CTX until modiﬁcation/
degradation is detected. After that, the degradation can be
evaluated but CTX cannot be quantiﬁed with the necessary
scientiﬁc rigor.
Table 4 summarizes the results of the stress study conducted to
evaluate the speciﬁcity of the method. The similarity factor (also
peak purity factor) for CTX QC sample was set at 99.3%. Due to the
inherent micro-heterogeneity of CTX [31], the spectra obtained
from the chromatographic peaks of fresh standard samples were
not identical (Fig. 2e), with the main dissimilarity observed be-
tween approximately λ¼220 and λ¼235 nm. As a result of these
slight spectral variations, peak purity analysis indicated impurities,
considering the reference value of the similarity factor, i.e., 99.3%
the default value for the ChemStation software [27]. This analysis
represents an attractive alternative to the use of a mass spectro-
metric detector for assessing peak purity, due to its cost/beneﬁts
and simplicity. These numerical methods for calculating similarity
based on the correlation coefﬁcient are also considered to be
suitable for assessing the degree of similarity between protein
absorption spectra [32]. In the stress study of CTX, spectral peak
purity was only assumed, i.e., no signiﬁcant changes were detected
compared with the CTX standard, when the similarity function
calculated for the corresponding chromatographic peak was
higher than 99.3%.
Modiﬁcation/degradation of CTX in medicine samples sub-
jected to stress conditions, both weak and strong, was detected
from the similarity factor value, i.e., below the ﬁxed value of 99.3%
as can be noted from results in Table 4. Fig. 3 shows the chro-
matograms of the stressed samples. Nevertheless, a new chro-
matographic peak clearly separated from the CTX peak was only
observed when samples were subjected to strong ionic and oxi-
dative stress. This new peak was observed at 1.7 min. Substances
at this short retention time were not retained in the column (re-
tention time of the front). In the case of the oxidative stress, this
peak could be attributed to the oxidation of methionine (Met), the
amino acid most susceptible to oxidation, the result of which is a
polar sulfonic group not retained in the column [33]. Other minor
modiﬁcations such as oxidation of aromatic amino acids (Trp, Tyr,
and Phe residues) [34, 35] and deamidation of speciﬁc amino acids
with the pH (mainly Asn and Gln residues) [33] produce slight
differences in the hydrophobicity relative to that of the intact CTX
that cannot be chromatographically detected by (RP)HPLC/DAD.
It is also worth highlighting that the formation of aggregates is
likely when mAbs are subjected to high temperatures or to light
due to unfolding or partial unfolding of the molecule [30,31]. The
results for CTX indicated that if the mAb underwent such con-
formational changes, they were not reﬂected in the chromato-
grams as new peaks. This means that these changes did not affect
the physicochemical chromatographic process, which indicated
that aggregates could not be separated on the RP column. The
Fig. 3. Stress study of medicine sample solutions of 2000 mg/L of CTX prepared in 0.9% NaCl. Stronger stress condition studied: (A) Temperature, 50 °C; (B) light stress;
(C) weak basic media; (D) strong basic media; (E) weak ionic stress; and (F) strong oxidative stress.
Table 4
Speciﬁcity study (stress study).
Stress type Stress intensity Similarity factor (%) Degradation peaks Decreased area under CTX peak (%) CTX peak deformation
Quality control – 99.3 No – No
Temperature 50°C 99.0 No 3.8 No
Light stress – 98.7 No 28.3 No
Ionic stress weak 99.3 No 7.8 No
strong 99.2 Yes 31.6 No
Oxidative media weak 99.1 No 10.1 No
strong 98.8 Yes 55.7 No
Acidic media weak 99.2 No 8.6 No
strong 99.1 No 31.1 No
Basic media weak 99.1 No 6.6 No
strong 98.9 No 33.2 No
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formation of aggregates. More research is currently being con-
ducted on this aspect using other forms of chromatography.
Therefore, from the point of view of the speciﬁcity of the pro-
posed (RP)HPLC/DAD method, the results of the stress study in-
dicated that the degraded or modiﬁed fraction of CTX could not be
chromatographically separated from the non-degraded CTX. Ef-
forts were made throughout the stress study to chromato-
graphically separate these different forms by modifying thegradient of the mobile phase, testing both more and less polar
phases, but the relatively slight differences in polarity of the de-
graded/modiﬁed forms of CTX prevented separate elution. Never-
theless, the procedure based on the three aspects cited above
could be used to detect slight modiﬁcations in the intact CTX, so
fulﬁlling in part the criterion for the speciﬁcity. For this reason, we
propose that the method be considered stability-indicating for
quantifying intact CTX, since it is qualiﬁed to detect degradation/
modiﬁcation in the mAb. Once these changes are detected, the
Table 5
Robustness study.
Variations Retention
time (min)
Symmetry
factor
Theoretical
plates
Capacity
factor
Flow rate (mL/
min)
1.0a 7.8 0.78 42333 3.51
0.9 8.2 0.68 35541 3.70
1.1 7.6 0.73 31626 3.38
Gradient varia-
tion (B %)b
30:60a 7.8 0.78 42333 3.51
25:55 8.8 0.72 41390 4.07
35:65 7.1 0.68 41089 3.08
Temperature
(°C)
70a 7.8 0.78 42333 3.51
68 7.5 0.72 39842 3.22
60 No peak
detected
a Selected chromatographic conditions for the HPLC method.
b Indicted as the modiﬁcation of B (%) in the gradient of the mobile phase.
Fig. 4. Graphical results of the long-term study of CTX sample solutions of
2000 mg/L prepared from dilution of Erbitux
s
in 0.9% NaCl.
Table 6
Long-term stability study results. Criteria to detect modiﬁcation/degradation in CTX
in solution at 2 mg/mL.
Day Similarity factor
(%)
Degradation
peaks
Intensity lost
(%)
Peak deformation
0 99.3 No – No
1 99.3 No 0.17 No
3 99.3 No 0.29 No
7 99.3 No 0.36 No
14 99.3 No 0.51 No
31 99.2 No 0.68 No
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different degraded forms of CTX cannot be chromatographically
separated. This means that the method fulﬁlls the ICH guidelines
in part, although not completely.
3.2.4. System suitability
The system suitability study focused on the evaluation of
parameters affected quantiﬁcation. In this way, CTX standard
samples at the targeted concentration (2 mg/mL) were used to
evaluate various chromatographic parameters i.e. the retention
time (7.8 min), symmetry factor (0.78), theoretical plates (42333)
and the capacity factor (3.51). The suitability of the analytical
system (instrumentþmethodþoperator) was demonstrated, as
these chromatographic parameters coincided with previously es-
tablished values (see Section 2). In addition, the reproducibility of
the injection volume (0.05% RSD for 1 μL) was less than that es-
tablished in the criteria (RSDr1%).
3.2.5. Robustness
The results of the study performed to evaluate the robustness
of the proposed method are summarized in Table 5. As expected,
the composition of the mobile phase and temperature were the
most important inﬂuences on the robustness. Indeed, when the
polarity of the mobile phase was increased, intact CTX was eluted
at a shorter retention time and overlapped with a peak at 7.1 min
from the base line. The same thing occurred when temperature
decreased to 68 °C. This was why the number of theoretical plates
was the highest when the mobile phase contained 35% phase B or
the column temperature was set at 68 °C (Table 5). Column
temperatureo60 °C caused notable deformation of the chroma-
tographic peak of intact CTX and prevented it from being analyzed.
At temperatures of465 °C, peak deformation was not detected,
although the area under the peak decreased slightly, probably due
to adsorption onto the column.
3.3. Assay of CTX in a long-term study (hospital conditions)
The proposed method was used to quantify and assess CTX
samples under hospital conditions in an ongoing long-term sta-
bility study. The study was conducted at a target concentration of
2.0 mg/mL, considered representative of the ﬁnal product whenadministered in hospital [25]. This study was performed in the
context of a wider project that seeks to implement and validate
analytical methods and protocols to characterize mAbs, with an
additional objective being to extend, if possible, the shelf lives of
these surplus biotechnological products used in hospital pharmacy
departments.
Fig. 4 shows the evolution of the CTX concentration for the
sample refrigerated at 4 °C. Table 6 summarizes the criteria to
detect the modiﬁcation/degradation of CTX to this study. These
results show a surprising stability for this mAb, indicating no
modiﬁcation/degradation for a month when stored at 4 °C, in
contrast to the results of studies we are currently performing on
other mAbs (some of which have already been published), in
which changes are detected after about a week [15]. We are cur-
rently conducting more studies using different liquid chromato-
graphic modes and by ELISA.4. Conclusions
This study contributes to demonstrating the suitability of
RP–LC coupled to DAD for the rigorous quantiﬁcation of
therapeutic intact monoclonal antibodies despite the inherent
complexity of this class of biotherapeutic drugs. In particular, we
proposed the rigorous quantiﬁcation of the intact CTX using a
simple, accurate and validated (RP)HPLC/DAD method. All the as-
pects considered in the validation procedure following the ICH
guidelines were successfully fulﬁlled except for those related to
the chromatographic separation of the different forms of the intact
CTX when degraded under speciﬁc stress conditions. This was
because the differences in the polarity are insufﬁcient to enable
degraded form of CTX to be chromatographically separated by
reverse-phase chromatography. Nevertheless, the method can be
considered stability-indicating as it is qualiﬁed to detect the
modiﬁcations in the intact CTX by applying the criteria proposed
A. Martínez-Ortega et al. / Journal of Pharmaceutical Analysis 6 (2016) 117–124124based on the analysis of the chromatograms and the spectral peak
purity. The method can, therefore, be used to test mAb stability in
both quality control processes and long-term stability studies, and
we should always bear in mind that biopharmaceuticals such as
mAbs should be analyzed and studied by various analytical
methods simultaneously. The proposed method here is only fo-
cused on quantiﬁcation aspects. Taking this into account, in ad-
dition to being simple, the method is also precise, accurate and
robust and it is a good alternative for the analysis of intact
therapeutic mAbs. The method also proved successful in quanti-
fying intact CTX in a long-term stability study, demonstrating its
usefulness for such purposes. This work is part of a wider project
that aims to propose rigorous analytical methods and validated
protocols for the study of marketed therapeutic mAbs. This
method represents only one of the analyses needed to characterize
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